Sales in the second quarter came in at 4.3 billion euros, in-line with expectations.\u00a0<\/p>\n
Stock Chart IconStock chart icon![\"hide](\"https:\/\/static-redesign.cnbcfm.com\/dist\/a54b41835a8b60db28c2.svg\")
<\/p>\n
Philips share price.<\/p>\n
\u2014 Matt Ward-Perkins, Jenni Reid<\/p>\n
Barclays beats Q2 profit estimates<\/p>\n
British bank\u00a0Barclays<\/a>\u00a0beat profit expectations and announced a \u00a31 billion ($1.33 billion) share buyback as market volatility boosted investment banking revenues.<\/p>\n Pre-tax profit beat estimates at \u00a32.5 billion ($3.34 billion) in the second quarter, compared with a mean LSEG forecast of \u00a32.23 billion. Group revenues met analyst projections of \u00a37.2 billion.<\/p>\n Read more here<\/a>.<\/p>\n \u2014 Jenni Reid <\/p>\n AstraZeneca posts better-than-expected second quarter results<\/p>\n A view of the AstraZeneca office in M\u00f6lndal, Sweden, on September 12, 2024.<\/p>\n Nurphoto | Getty Images<\/p>\n AstraZeneca on Tuesday posted better-than-expected second quarter earnings, driven by demand for key cancers and biopharmaceutical products, and reiterated its commitment to expanding the business in the U.S.<\/p>\n The Anglo-Swedish pharma firm posted revenues of $14.46 billion over the three-month period to June 30, ahead of the $14.07 billion estimated by analysts in an LSEG poll.<\/p>\n Quarterly adjusted core operating profit came in at $4.58 billion versus $4.48 billion anticipated.<\/p>\n The FTSE 100 company maintained its full-year forecast for revenues to rise by a high single-digit percentage, despite geopolitical challenges, and cited its ambitions to grow its U.S. footprint to deliver $80 billion revenue by 2030.<\/p>\n AstraZeneca said last week it plans to invest $50 billion<\/a> in bolstering its U.S. manufacturing and research capabilities by 2030, becoming the latest pharmaceutical firm to ramp up its stateside spending in the wake of U.S. trade tariffs.<\/p>\n \u2014 Karen Gilchrist<\/p>\n Opening calls<\/p>\n Good morning from London.<\/p>\n European stock markets are heading for a higher open today, according to IG data, with major bourses heading for gains of around 0.2%.<\/p>\n On Monday, initial optimism over the EU-U.S. framework trade deal<\/a> faded by the end of the session to leave the Stoxx 600 index at a 0.23% loss. Investors will continue to hunt for any clarity on the outlook today \u2014 particularly as uncertainty remains for sectors including pharmaceuticals, and key products like spirits<\/a>.<\/p>\n “We see the tentative trade deal with the EU as pretty much completing the run of good trade news that has lifted global confidence and equity markets, and weakened the [U.S. dollar],” Standard Chartered macro strategist Steve Englander said in a Monday note.<\/p>\n “The deals are a negative from a global growth perspective but appear to be something that US trading partners can live with.”<\/p>\n Earnings are also in focus, with British bank Barclays<\/a> reporting shortly. Results are also out from L’Or\u00e9al<\/a>, AstraZeneca<\/a> and Ferrovial<\/a>, along with Boeing<\/a>, Starbucks<\/a>, Visa<\/a>, PayPal<\/a> and more Stateside.<\/p>\n \u2014 Jenni Reid<\/p>\n","protected":false},"excerpt":{"rendered":"Philips jumps on improved tariff outlook Shares of Philips soared nearly 14% at the market open, after the…\n","protected":false},"author":3,"featured_media":82468,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[133,64,81,13656,135,134,67,132,68],"class_list":{"0":"post-101548","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-breaking-news-markets","9":"tag-business","10":"tag-business-news","11":"tag-earnings","12":"tag-markets","13":"tag-stock-markets","14":"tag-united-states","15":"tag-unitedstates","16":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114935471995592691","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/101548","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=101548"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/101548\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/82468"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=101548"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=101548"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=101548"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}